The French Experience of Pharmacists and CAR T‐Cells: A Study of the French Society of Oncology Pharmacy (SFPO)
Hematological Oncology · 2025-11 · 43 (6)
DOI: 10.1002/hon.70144 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Hematological Oncology, online erschienen am 22.10.2025. Verfasst von Vérane Schwiertz und 19 weiteren Autor:innen. Beteiligte Einrichtung: SFPO Société Française de Pharmacie Oncologique, Paris, France. Hauptthemen laut MEDLINE: Pharmacists, Immunotherapy, Adoptive, Receptors, Chimeric Antigen, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The aim of this study was to describe the initial 3‐year experience in vein‐to‐vein time for axi‐cel therapy and the role of pharmacists in the first recruiting French centers. Retrospective observational data were collected for vein‐to‐vein time for commercial axi‐cel after ≥ 2 lines of systemic therapy between January 2019 and December 2021 in the first 12 authorized French centers. Hospital pharmacists used a circuit database to ensure the prospective traceability at all steps. Totally 501 of the 562 intention‐to‐treat registrations on the database for cytapheresis (89,1%) led to the infusion of axi‐cel. Median vein‐to‐vein time was shortened by 4 days. This was mainly due to tightening the interval from apheresis to release. The 36‐day median vein‐to‐vein time achieved after 3 years' experience should be compared to the 29–34 days reported in Canada, the USA and Israel, where manufacturing sites are geographically closer to hospital centers than they are in France. The top 5 recruiting centers had the shortest vein‐to‐vein times. This French experience may serve as a model for other European centers, notably as regards deployment of pharmacists to improve the patient pathway with CAR T‐cells and other gene and cellular therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- SFPO Société Française de Pharmacie Oncologique, Paris, France.
- Pharmacie, Groupement Hospitalier Sud, Hospices Civils de Lyon, Lyon, France.
- Pharmacie, Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris, Paris, France.
- Pharmacie, CHU de Montpellier, Montpellier, France.
- Pharmacie, CHU de Rennes, Rennes, France.
- Pharmacie, CHRU de Lille, Lille, France.
ORCID-Profile: Bertrand Pourroy, Florence Ranchon
Zitieren
APA
Schwiertz, V., de Jorna, R., Quintard, A., Lester, M. A., Pinturaud, M., Cormier, N., D'Huart, E., Fougereau, E., Carvalho, M., Sourisseau, B., Gueneau, P., Wasiak, M., Jouvance, A., Paul, M., Chevrier, R., Pourroy, B., Cazin, J. L., Ranchon, F., Madelaine-Chambrin, I., & Rioufol, C. (2025). The French Experience of Pharmacists and CAR T‐Cells: A Study of the French Society of Oncology Pharmacy (SFPO). Hematological Oncology, 43(6). https://doi.org/10.1002/hon.70144
Vancouver
Schwiertz V, de Jorna R, Quintard A, Lester MA, Pinturaud M, Cormier N, et al. The French Experience of Pharmacists and CAR T‐Cells: A Study of the French Society of Oncology Pharmacy (SFPO). Hematological Oncology. 2025;43(6). doi:10.1002/hon.70144
BibTeX
@article{Schwiertz2025,
author = {Schwiertz, Vérane and de Jorna, Romain and Quintard, Adeline and Lester, Marie-Antoinette and Pinturaud, Marine and Cormier, Nicolas and D'Huart, Elise and Fougereau, Emmanuelle and Carvalho, Muriel and Sourisseau, Benjamin and Gueneau, Pauline and Wasiak, Mathieu and Jouvance, Alexia and Paul, Muriel and Chevrier, Régine and Pourroy, Bertrand and Cazin, Jean-Louis and Ranchon, Florence and Madelaine-Chambrin, Isabelle and Rioufol, Catherine},
title = {The French Experience of Pharmacists and CAR T‐Cells: A Study of the French Society of Oncology Pharmacy (SFPO)},
journal = {Hematological Oncology},
year = {2025},
volume = {43},
number = {6},
doi = {10.1002/hon.70144}
}
EUVIMED